1-(1-adamantyl)-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]butan-2-one
C30H31Cl3N2O — CID 163711398
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-(1-adamantyl)-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]butan-2-one
1-(1-adamantyl)-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]butan-2-one (PubChem CID 163711398) has the molecular formula C30H31Cl3N2O and a molecular weight of 541.95 g/mol. Its IUPAC name is 1-(1-adamantyl)-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]butan-2-one.
Molecular Properties
| Compound Name | 1-(1-adamantyl)-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]butan-2-one |
|---|---|
| PubChem CID | 163711398 |
| Molecular Formula | C30H31Cl3N2O |
| Molecular Weight | 541.95 g/mol |
| Exact Mass | 540.15 |
| IUPAC Name | 1-(1-adamantyl)-4-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]butan-2-one |
| SMILES | Cc1c(CCC(=O)CC23CC4CC(CC(C4)C2)C3)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| InChI | InChI=1S/C30H31Cl3N2O/c1-18-27(8-7-25(36)17-30-14-19-10-20(15-30)12-21(11-19)16-30)34-35(28-9-6-24(32)13-26(28)33)29(18)22-2-4-23(31)5-3-22/h2-6,9,13,19-21H,7-8,10-12,14-17H2,1H3 |
| InChIKey | CFZLUWFNXDULAL-UHFFFAOYSA-N |
| XLogP | 8.92 |
| TPSA | 34.89 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 541.95 |
| LogP ≤ 5 | 8.92 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163711398 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.